giovedì, 27 marzo 2025

Notizie AIOM – anno XVII n. 718

FDA Lowers Pembrolizumab PD-L1 Cutoff in NSCLC, Expands Approval to Stage III

April 11, 2019 - The FDA has expanded the approval for pembrolizumab monotherapy for the frontline treatment of patients with stage III non–small cell lung cancer (NSCLC), who are ineligible for surgery or definitive chemoradiation, or metastatic NSCLC, with a PD-L1 ...
Leggi tutto

Opioid-Related Hospitalizations Among Patients With Cancer in the United States

April 12, 2019 - In a study reported in a research letter in JAMA Oncology, Chua et al found that opioid-related hospitalizations among American patients with cancer are rare, increasing at a very low rate, and consist mostly of hospitalization for nonheroin opioid poisoning. ...
Leggi tutto

FDA approves first targeted therapy for metastatic bladder cancer

April 12, 2019 - The U.S. Food and Drug Administration today granted accelerated approval to Erdafitinib, a treatment for adult patients with locally advanced or metastatic bladder cancer that has a type of susceptible genetic alteration known as FGFR3 or FGFR2, and that ...
Leggi tutto

Update of EU recommendations for 2019/2020 seasonal flu vaccine composition

April 12, 2019 - EMA has issued an PDF iconupdate of the EU recommendations for the influenza virus strains that vaccine manufacturers should include in vaccines for the prevention of seasonal influenza from autumn 2019. The recommendations now also contain a decision on ...
Leggi tutto

Entrectinib Data Highlighted as FDA Weighs Approval for ROS1+ NSCLC

April 11, 2019 - Patients with ROS1-positive non–small cell lung cancer (NSCLC) showed high response rates and durable responses following treatment with entrectinib, according to findings from a pooled analysis of 3 studies presented at the 2019 European Lung Cancer ...
Leggi tutto

Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real‐World Practice

Several immune checkpoint inhibitor therapies (CPIs) have been approved to treat metastatic urothelial cell carcinoma (mUC). Because of the favorable toxicity profile of CPI compared with chemotherapy, oncologists may have a low threshold to prescribe CPI to patients near ...
Leggi tutto

The role of regulators in establishing added benefit of novel therapies

April 11, 2019 - Regulators have a role to play in ensuring that there is a solid evidence base to support the assessment of added therapeutic benefit of novel treatments compared with existing and potentially cheaper therapies. To help health technology assessment bodies, ...
Leggi tutto

Olaparib Approved in Europe for BRCA+ Breast Cancer

April 10, 2019 - The European Commission has approved olaparib for the treatment of adult patients with germline BRCA1/2-mutant, HER2-negative locally advanced or metastatic breast cancer. The decision is based on findings from the phase III OlympiAD trial, in which the ...
Leggi tutto

HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer

HER2 amplification is detected in 3% of patients with colorectal cancer (CRC), making tumors in the metastatic setting vulnerable to double pharmacological HER2 blockade. Preclinical findings show that it also might impair response to anti-epidermal growth factor receptor ...
Leggi tutto

The role of patient-reported outcomes in outpatients receiving active anti-cancer treatment: impact on patients’ quality of life

Patient-reported outcomes (PROs) are the gold standard to describe subjective symptoms. Nurses can be successfully involved in collecting symptom information, because of their direct relationship with the patient. In order to improve clinical management of outpatients receiving ...
Leggi tutto